Types of Research
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove 2013 filter 2013
- (-) Remove Gender filter Gender
- (-) Remove Southern Africa Region and Selected Countries filter Southern Africa Region and Selected Countries
- (-) Remove Research & Development filter Research & Development
- (-) Remove Global filter Global
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
In this brief we analyze patterns of intercropping and differences between intercropped and monocropped plots among smallholder farmers in Tanzania using data from the 2008/2009 wave of the Tanzania National Panel Survey (TZNPS), part of the Living Standards Measurement Study – Integrated Surveys on Agriculture (LSMS-ISA). Intercropping is a planting strategy in which farmers cultivate at least two crops simultaneously on the same plot of land. In this brief we define intercropped plots as those for which respondents answered “yes” to the question “Was cultivation intercropped?” We define “intercropping households” as those households that intercropped at least one plot at any point during the year in comparison to households that did not intercrop any plots. The analysis reveals few significant, consistent productivity benefits to intercropping as currently practiced. Intercropped plots are not systematically more productive (in terms of value produced) than monocropped plots. The most commonly cited reason for intercropping was to provide a substitute crop in the case of crop failure. This suggests that food and income security are primary concerns for smallholder farmers in Tanzania. A separate appendix includes the details for our analyses.